X-tosis is leading a groundbreaking approach to treat Alzheimer’s and Parkinson’s diseases by addressing mitochondrial dysfunction. Our innovative therapies target VDAC1 oligomerization, a critical driver of cell death and inflammation in neurodegenerative disorders. Built on more than two decades of research and validated by dozens of independent groups, our approach safeguards neuronal health and optimizes cellular function. X-tosis aims to halt disease progression and dramatically improve patients' quality of life worldwide.